Skip to main content
. 2017 Dec 28;9(3):4109–4119. doi: 10.18632/oncotarget.23751

Figure 3.

Figure 3

(A) Mutation burden of MOC22 and MOC2 and predicted neoantigen burden (IC50<50nM) in each tumor. (B, C) Manhattan plot of affinity score (1/IC50)*100 of top candidate neoantigens in MOC2 and MOC22. Labeled are the selected highest predicted binding affinity candidate neoantigens in each tumor cell line.